1. Home
  2. CCO vs ERAS Comparison

CCO vs ERAS Comparison

Compare CCO & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCO
  • ERAS
  • Stock Information
  • Founded
  • CCO 1995
  • ERAS 2018
  • Country
  • CCO United States
  • ERAS United States
  • Employees
  • CCO N/A
  • ERAS N/A
  • Industry
  • CCO Advertising
  • ERAS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CCO Consumer Discretionary
  • ERAS Health Care
  • Exchange
  • CCO Nasdaq
  • ERAS Nasdaq
  • Market Cap
  • CCO 472.0M
  • ERAS 432.6M
  • IPO Year
  • CCO 2005
  • ERAS 2021
  • Fundamental
  • Price
  • CCO $0.96
  • ERAS $1.16
  • Analyst Decision
  • CCO Buy
  • ERAS Strong Buy
  • Analyst Count
  • CCO 3
  • ERAS 6
  • Target Price
  • CCO $2.05
  • ERAS $4.83
  • AVG Volume (30 Days)
  • CCO 2.7M
  • ERAS 2.3M
  • Earning Date
  • CCO 05-01-2025
  • ERAS 05-07-2025
  • Dividend Yield
  • CCO N/A
  • ERAS N/A
  • EPS Growth
  • CCO N/A
  • ERAS N/A
  • EPS
  • CCO N/A
  • ERAS N/A
  • Revenue
  • CCO $1,505,230,000.00
  • ERAS N/A
  • Revenue This Year
  • CCO $6.83
  • ERAS N/A
  • Revenue Next Year
  • CCO $3.73
  • ERAS N/A
  • P/E Ratio
  • CCO N/A
  • ERAS N/A
  • Revenue Growth
  • CCO 4.95
  • ERAS N/A
  • 52 Week Low
  • CCO $0.81
  • ERAS $1.01
  • 52 Week High
  • CCO $1.88
  • ERAS $3.45
  • Technical
  • Relative Strength Index (RSI)
  • CCO 39.42
  • ERAS 41.47
  • Support Level
  • CCO $0.89
  • ERAS $1.01
  • Resistance Level
  • CCO $1.04
  • ERAS $1.29
  • Average True Range (ATR)
  • CCO 0.10
  • ERAS 0.17
  • MACD
  • CCO 0.00
  • ERAS 0.00
  • Stochastic Oscillator
  • CCO 44.12
  • ERAS 31.25

About CCO Clear Channel Outdoor Holdings Inc.

Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: